• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Wexler William A.

    2/10/25 7:00:13 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ERNA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Wexler William A.

    (Last) (First) (Middle)
    C/O ETERNA THERAPEUTICS INC.
    1035 CAMBRIDGE STREET, SUITE 18A

    (Street)
    CAMBRIDGE MA 02141

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Eterna Therapeutics Inc. [ ERNA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    02/07/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $0.34 02/07/2025 A 124,533 (1) 02/07/2035 Common Stock 124,533 $0 124,533 D
    Explanation of Responses:
    1. Subject to continued service, one-third of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 24 substantially equal monthly installments thereafter.
    /s/ William Wexler 02/10/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ERNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ERNA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ERNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Cherington Charles bought $2,000,000 worth of shares (4,000,000 units at $0.50), increasing direct ownership by 144% to 6,779,440 units (SEC Form 4)

    4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

    2/17/26 9:14:34 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sr. VP of Finance Gurrola Sandra M converted options into 30 shares, increasing direct ownership by 38% to 110 units (SEC Form 4)

    4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

    7/7/25 8:00:05 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Cherington Charles bought $2,221,826 worth of shares (21,241,163 units at $0.10), increasing direct ownership by 104% to 41,659,743 units (SEC Form 4)

    4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

    6/11/25 8:34:12 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Cherington Charles bought $2,000,000 worth of shares (4,000,000 units at $0.50), increasing direct ownership by 144% to 6,779,440 units (SEC Form 4)

    4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

    2/17/26 9:14:34 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Cherington Charles bought $2,221,826 worth of shares (21,241,163 units at $0.10), increasing direct ownership by 104% to 41,659,743 units (SEC Form 4)

    4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

    6/11/25 8:34:12 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Large owner Cherington Charles bought 13,252,112 shares, increasing direct ownership by 2,381% to 13,808,577 units (SEC Form 4)

    4/A - Ernexa Therapeutics Inc. (0000748592) (Issuer)

    5/7/25 11:48:22 AM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Three Biotechs Deliver Catalysts to Watch

    DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Today’s announcements from NeOnc Technologies (NASDAQ:NTHI), Ernexa Therapeutics (NASDAQ:ERNA), and VivoSim Labs (NASDAQ:VIVS) highlight three distinct pathways to potential value creation. NeOnc Technologies NeOnc Technologies (NASDAQ:NTHI) announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, NEO212, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other central nervous system cancers. Rather than proceeding with its scheduled Type B

    7/15/26 10:42:42 AM ET
    $NTHI
    $ERNA
    $VIVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry

    Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND  ERNA-101 Plus Anti-PD-1 Achieved Complete Tumor Clearance and Long-Term Survival in Two-Thirds of Treated Animals While No Complete Responses Were Observed in Any Monotherapy or Control Group IND Submission Planned for Q3 2026 with First-in-Human Phase 1 Trial Expected to Begin in Q4 2026 CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced compelling new precli

    7/15/26 7:50:00 AM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026

    CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into tumors the immune system can recognize and kill Video highlights compelling preclinical data, differentiated off-the-shelf iMSC platform and progress toward planned first-in-human clinical evaluation IND submission planned for the third quarter of 2026 with first-in-human Phase 1 study anticipated to begin in the fourth quarter of 2026 Access the Ernexa CEO Corner here CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today released a new installment of

    7/14/26 9:01:00 AM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERNA
    SEC Filings

    View All

    Ernexa Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

    7/2/26 4:40:47 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ernexa Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

    7/2/26 4:30:32 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ernexa Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

    6/26/26 4:30:19 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERNA
    Financials

    Live finance-specific insights

    View All

    Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

    The Company's operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead program, ERNA-101, toward first-in-human Phase 1 study in platinum-resistant ovarian cancer (PROC), anticipated in H2 2026 CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced its financial results for the three- and nine-month periods ended September 30, 2025, and highlighted its continued operational execution. Recent Highlights Announced a cel

    11/10/25 8:35:00 AM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

    CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) --  Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the execution of a securities purchase agreement with accredited investors for the sale of approximately $9.2 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase an aggregate of 9,579,014 shares of common stock in a private placement transaction that was priced at-the-market under Nasdaq rules. The Company expects to hold an initial closing at which it exp

    12/14/23 6:56:25 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing

    CAMBRIDGE, MASS., July 18, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the execution and closing of the sale of approximately $8.7 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase common stock in a private placement transaction that closed on July 14, 2023 and was priced at-the-market under Nasdaq rules. The notes, which were issued at par, bear interest at a rate of 6.0% per year, payable quarterly, and mature in July 2028

    7/18/23 8:00:00 AM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERNA
    Leadership Updates

    Live Leadership Updates

    View All

    Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG

    CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of Dr. Ira S. Winer, M.D., Ph.D., FACOG, to its Scientific and Medical Advisory Board. Dr. Winer is a nationally recognized gynecologic oncologist and translational scientist. His expertise in women's oncology, immunotherapy, and early-phase clinical development further strengthens Ernexa's capabilities as it advances its proprietary induced mesenchymal stem cells (iMSC) platform and lead program, ERNA-101, toward key milestones, including first-in-human tria

    12/2/25 8:50:00 AM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

    CAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (NASDAQ:ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the appointment of Elena Ratner, M.D., M.B.A, to the Board of Directors. Dr. Ratner will spearhead the strategic direction of Eterna's efforts to combat ovarian cancer, leveraging her extensive expertise in obstetrics, gynecology, and reproductive sciences. Under her leadership, the company aims to accelerate advancements in innovative therapies targeting these high-priority areas in women's health. This direction is bolstered by Eterna's recent collaboration with MD Anderson Cancer Center. Announced last month, the p

    1/9/25 7:30:00 AM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

    CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a preclinical-stage biopharmaceutical company, committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announces the appointment of Mahendra Rao, PhD, to its scientific advisory board. "We're honored to have Dr. Mahendra Rao join our Scientific Advisory Board," said Sanjeev Luther, President and CEO of Eterna. "His deep scientific expertise in regenerative medicine and cell engineering will be invaluable to our company in its upcoming phases of scientific and clinical development as we strive to brin

    5/8/24 9:31:43 AM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care